$XNCR News
Last published 2d ago
- 2d agoXNCRXencor Presents Initial Plamotamab Data in Rheumatoid Arthritis at ACR Convergence 2026 and Updates Progress in First-in-Human Study of XmAb657Business WirePASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced initial dose-escalation data from its ongoing Phase 1b study of subcutaneous plamotamab, a bispecific CD20 x CD3 T-cell engager, in adults with rheumatoid arthritis. The data are being present ...
- 1w agoXNCRXencor Inc - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 2w agoXNCRXENCOR TRIAL RESULTS WEBCAST - XENCOR INCEarnings Call TranscriptsHello and welcome to the Zencore ESMO 2026 webcast. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session.
- 2w agoXNCRXENCOR TRIAL RESULTS WEBCAST - XENCOR INCEarnings Call TranscriptsHello and welcome to the Zencore ESMO 2026 webcast. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session.
- 2w agoXNCRXencor Trial Results Webcast - XENCOR INCEarnings Call TranscriptsHello and welcome to the Zencore ESMO 2026 webcast. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session.
- 2w agoXNCRXencor Trial Results Webcast - XENCOR INCEarnings Call TranscriptsHello and welcome to the Zencore ESMO 2026 webcast. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session.
- 2w agoNTHIAVBPXNCRDefining Moments in the Race for Biotech BreakthroughsGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major
- 2w agoXNCRXencor Inc - PRESENTATION DATED OCTOBER 26, 2026Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 8.01 Item 9.01
- 2w agoXNCRXencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ TumorsBusiness Wire-- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC
- 3w agoXNCRXencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a webcast on Monday, October 26 at 7:00 a.m. EDT
- 3mo agoXNCRXencor Reports Second Quarter 2026 Financial ResultsBusiness Wire-- XmAb819 ccRCC expansion cohorts to be presented in an oral session at ESMO 2026; multiple Phase 1 sub-studies in earlier lines of therapy and additional indications now open for enrollment or planned -- -- XmAb942
- 3mo agoXNCRXencor to Receive $105 Million From Alexion to Resolve Ultomiris® U.S. Royalty MatterBusiness Wire-- Agreement with Alexion resolves previously disclosed dispute regarding U.S. royalties ---- Ex-U.S. royalties remain unchanged --Xencor, Inc. (NASDAQ:XNCR) ("Xencor"), a clinical-stage biopharmaceutical
- 3mo agoXNCRXencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness Wire-- ESMO presentation to highlight expansion-cohort results for IV doses evaluated for recommended Phase 3 dose ---- Pivotal study of XmAb819 monotherapy in advanced ccRCC, planned to begin in 2027 --Xencor, Inc.
- 5mo agoARGXCGEMHYFTIDXX+2The Biology Came First.Business WireOver 20 partner-owned drug programs have reached clinical trials as a result of antibody discovery work performed by MindWalk scientists — ten currently in active Phase 1–3. The same scientific depth and biological
- 6mo agoXNCRXencor Reports First Quarter 2026 Financial ResultsBusiness Wire-- XmAb819 clear cell renal cell carcinoma (ccRCC) expansion cohort results to be presented at a medical conference in 2H26 -- -- XmAb412 (TL1A x IL23p19) first-in-human healthy participant study on-track for 3Q26
- 6mo agoXNCRXENCOR DDW 2026 WEBCAST - XENCOR INCEarnings Call Transcriptsyou you you you you you you you you you Thanks for watching! We'll be right back. We'll be right back. Thank you. Take care. you Hi, this is the audio and video check. Testing 1, 2, 3, 4, 5. This is the audio and video c
- 6mo agoXNCRXencor to Host Webcast to Discuss XmAb942 and XmAb412 Data Presentations at DDWBusiness Wire-- Data support potentially best-in-class profile of XmAb942, under evaluation in ongoing global Phase 2b XENITH-UC study on track for 12-week induction results in 2027 -- -- Novel XenLock™ format optimizes
- 8mo agoXNCRXencor Announces Change to Ultomiris® Royalty Revenue ForecastBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that Alexion Pharmaceuticals, Inc. (the
- 8mo agoXNCRXencor Reports Fourth Quarter and Full Year 2025 Financial ResultsBusiness Wire-- XmAb819, novel first-in-class ENPP3 x CD3 T-cell engaging bispecific antibody, Phase 1 dose expansion in CRC, NSCLC and pRCC open to enrollment; on track to present clinical data to support a recommended Phase 3 dose
- 8mo agoXNCRXencor to Participate at Upcoming Investor ConferencesBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at
- 11mo agoXNCRXencor Announces Extension of U.S. Patent Term on Certain Xtend™ AntibodiesBusiness Wire-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty revenue
- 11mo agoXNCRXENCOR, INC. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 1y agoXNCRXencor to Participate at Upcoming Investor ConferencesBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at
- 1y agoXNCRXencor Reports Third Quarter 2025 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third quarter ended
- 1y agoXNCRXencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell CarcinomaBusiness Wire-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion cohort has been selected; dose
- 1y agoXNCRXencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell CarcinomaBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday, October 24
- 1y agoGTBPEVAXRNXTEDAP+1Natural Killer Cell Therapies Lead $254B Immunotherapy Market TransformationPR NewswireEquity InsiderNews Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more...
- 1y agoXNCRXencor Announces Presentation of Initial Phase 1 Dose-Escalation Results of XmAb819 in Clear Cell Renal Cell Carcinoma at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer TherapeuticsBusiness Wire-- Management to host webcast and conference call on Friday, October 24, 2025 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and
- 1y agoMRUSXNCRMerus N.V. vs Xencor, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoMRUSXNCRMerus N.V. vs Xencor, Inc. - AIA Trial, Institution GrantedUS Patent Trial and Appeal Board
- 1y agoXNCRXencor to Participate at Upcoming Investor ConferencesBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will participate at
- 1y agoXNCRXencor Reports Second Quarter 2025 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the second quarter ended
- 1y agoXNCRXencor Appoints Raymond Deshaies, Ph.D., to Board of DirectorsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Raymond J. Deshaies, Ph.D.,
- 1y agoXNCRXencor Reports First Quarter 2025 Financial ResultsBusiness Wire-- Recent interim Phase 1 study results for XmAb942 (Xtend™ anti-TL1A) support a 12-week maintenance dosing interval in XENITH-UC, a Phase 2b study in participants with ulcerative colitis, to begin in the second
- 1y agoXNCRXencor Announces Positive Interim Results From First-in-Human Healthy Volunteer Study of XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, in Development for Treatment of Inflammatory Bowel DiseaseBusiness Wire-- XENITH-UC, a Phase 2b study of XmAb942 in participants with ulcerative colitis, to begin in the second half of 2025 -- -- Single and multiple doses of XmAb942 are well tolerated and safety profile is consistent with
- 1y agoXNCRXencor Appoints Todd Simpson to Board of DirectorsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board
- 1y agoXNCRXencor Reports Fourth Quarter and Full Year 2024 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and
- 1y agoXNCRXencor to Participate at Upcoming Investor ConferencesBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at
- 2y agoXNCRXencor Reports Third Quarter 2024 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the third quarter
- 2y agoXNCRXencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel DiseaseBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has initiated dosing of healthy
- 2y agoXNCRXencor Presents Preclinical Data on XmAb942, a High-Potency Extended Half-Life Anti-TL1A Antibody, to be Developed for Patients with Inflammatory Bowel DiseasesBusiness Wire-- XmAb942 on track for first subject dosing in Phase 1 healthy volunteer study in Q4 2024 -- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of
- 2y agoXNCRXencor Announces Upcoming Change to Board of DirectorsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that Dagmar Rosa-Bjorkeson has informed the
- 2y agoXNCRXencor Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesBusiness WireXencor, Inc. ("Xencor") (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the closing of its previously
- 2y agoXNCRXencor Announces Pricing of $175 Million Public Offering of Common StockBusiness WireXencor, Inc. ("Xencor") (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the pricing of its underwritten
- 2y agoXNCRXencor Announces Proposed Public Offering of Common StockBusiness WireXencor, Inc. ("Xencor") (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that it has commenced an
- 2y agoXNCRXencor Announces XmAb Drug Candidates in Autoimmune Disease with Near-Term Clinical Plans and Shares Clinical Progress in Early-Stage Oncology ProgramsBusiness Wire– Phase 1 healthy volunteer study of half-life extended anti-TL1A antibody XmAb942 to dose first subject in Q4 2024, with data anticipated in the first half of 2025 – – XmAb® T-cell engagers plamotamab (CD20 x
- 2y agoXNCRXencor to Host Research & Development Webcast and Conference Call on Monday, September 9, 2024Business WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that management will host a webcast and
- 2y agoXNCRXencor Reports Second Quarter 2024 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the second quarter
- 2y agoXNCRXencor Regains CD20 x CD3 Bispecific T-Cell EngagerBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, announced it will regain exclusive worldwide rights to
- 2y agoXNCRXencor Reports First Quarter 2024 Financial ResultsBusiness WireXencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the first quarter